

1 **Dengue in Cambodia 2002-2020: Cases, Characteristics and Capture by**

2 **National Surveillance**

3 Christina Yek¹, Yimei Li², Andrea R. Pacheco³, Chanthap Lon³, Veasna Duong⁴, Philippe
4 Dussart^{4#}, Sophana Chea³, Sreyngim Lay³, Somnang Man³, Souv Kimsan⁵, Chea Huch⁵, Rithea
5 Leang⁵, Rekol Huy⁵, Cara E. Brook², Jessica E. Manning⁶

6 ¹Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda,
7 MD, USA

8 ²Department of Ecology and Evolution, University of Chicago, Chicago, IL, USA

9 ³International Center of Excellence in Research, National Institute of Allergy and Infectious
10 Diseases, Phnom Penh, Cambodia

11 ⁴Virology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia

12 ⁵National Center of Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom
13 Penh, Cambodia

14 ⁶Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious
15 Diseases, Rockville, MD, USA

16 # Present address: Institut Pasteur de Madagascar, Antananarivo, Madagascar

17

18 **Corresponding author:**

19 Jessica Manning

20 Email: jessica.manning@nih.gov

21 Mailing address: 12735 Twinbrook Parkway 2E-32A, Rockville, MD 20852

22 Telephone: +1 240 731 4938

23

24 **Running title:** Dengue Epidemiology in Cambodia

25 **Keywords:** Dengue, Cambodia, Disease Surveillance, Demographic Transitions

26 **Word count:** Abstract 225; Manuscript 3071

27 **Figures:** 3 **Tables:** 2

28 **Abstract**

29

30 **Objective**

31 Data from 19 years of national dengue surveillance in Cambodia (2002-2020) were analyzed to
32 describe trends in dengue case characteristics and incidence.

33

34 **Methods**

35 Generalized additive models were fitted to dengue case incidence and characteristics (mean age,
36 case phenotype, fatality) over time. Dengue incidence in a pediatric cohort study (2018-2020)
37 was compared to national data during the same period to evaluate disease under-estimation by
38 national surveillance.

39

40 **Findings**

41 During 2002-2020, there were 353,270 cases of dengue (average age-adjusted incidence 1.75
42 cases/ 1,000 persons/ year) recorded in Cambodia, with an estimated 2.1-fold increase in case
43 incidence between 2002 and 2020 (slope = 0.0058, SE = 0.0021, p = 0.006). Mean age of
44 infected individuals increased from 5.8 years in 2002 to 9.1 years in 2020 (slope = 0.18, SE =
45 0.088, p <0.001); case fatality rates decreased from 1.77% in 2002 to 0.10% in 2020 (slope = -
46 0.16, SE = 0.0050, p <0.001). When compared to cohort data, national data under-estimated
47 clinically apparent dengue case incidence by 5.0-fold (95% CI 0.2 – 26.5), and overall dengue
48 case incidence (both apparent and inapparent cases) by 33.6-fold (range: 18.7- 53.6).

49

50 **Conclusion**

51 Dengue incidence in Cambodia is increasing and disease is shifting to older pediatric
52 populations. National surveillance continues to under-estimate case numbers. Future
53 interventions should account for disease under-estimation and shifting demographics for scaling
54 and to target appropriate age groups.

55 **Introduction**

56 The global incidence of dengue is on the rise. Cases increased by 8-fold over the last two
57 decades, with the greatest number of cases recorded in 2019.¹ Experts attribute this trend to a
58 variety of viral, vector, host, and ecologic factors including high rates of population growth in
59 endemic areas, rapid unplanned urbanization without simultaneous expansion of vector control
60 and water management systems, increasing global connectivity, and climate change expanding
61 the geographic range of the *Aedes spp.* mosquito, among others.²

62
63 Accurate estimates of dengue burden are crucial to ensure appropriate allocation of resources to
64 contain infection and manage clinical disease. The development of novel quadrivalent vaccines
65 has added urgency to the task as public health entities plan vaccine rollouts in dengue-endemic
66 areas.³⁻⁵ However, the most heavily-afflicted countries rely on resource-scarce national
67 surveillance systems with predominantly clinicosyndromic case identification and passive
68 reporting, leading to gross under-estimation of disease burden.⁶ One approach to this issue
69 involves drawing data from active cohort surveillance and applying an expansion factor (i.e., the
70 ratio of detected dengue cases to those in official reports) to estimate true incidence within the
71 overall population.⁶ However, most active surveillance studies rely on the detection of
72 symptomatic cases at select diagnostic centers, overlooking the majority of people that may have
73 clinically inapparent infection or do not seek care for other reasons.⁷ Capturing this population of
74 inapparent cases is vital to understand disease pathogenesis and host immunity, and importantly,
75 for design and evaluation of containment strategies.⁸ Cross-sectional serosurveillance of dengue
76 captures prior infection, both clinically apparent and inapparent. Where age-stratified data is
77 available, this can be used to calculate transmission intensity (i.e., force of infection, defined as
78 the rate at which susceptible individuals become infected) with practical applications including
79 defining target populations for pre-vaccination serologic screening.⁹ Serosurveillance studies
80 applying techniques such as plaque reduction neutralization assays (PRNT) can provide
81 serotype-specific granularity and are less subject to cross-reactivity with other endemic
82 flaviviruses than ELISA-based serologic assays.¹⁰ Finally, longitudinal serosurveillance provides
83 the most accurate capture by removing assumptions about incidence rate constancy over time or
84 age group. However, such methods are resource-intensive and impractical to guide public policy
85 at a national level.¹¹

86
87 The World Health Organization (WHO) region of Southeast Asia (SEA) includes ten dengue-
88 endemic countries that comprise 70% of dengue cases worldwide.¹ Among these is Cambodia, a
89 country in the Indochinese peninsula with a population of 17 million. National dengue
90 surveillance data for Cambodia was last published in 2010.¹² This report covered a period of
91 dynamic change from 1980 to 2007 during which post-civil war improvements in public health
92 infrastructure led to improved surveillance efforts including several sentinel sites in the early
93 2000s. Since the publication of this report, Cambodia has continued to undergo marked changes
94 in population demographics and urbanization. However, national dengue surveillance continues
95 to have several limitations including reliance on self-referral, predominant clinicosyndromic
96 identification, exclusion of private sector practices, and a largely passive reporting system
97 dependent on variable participation of provincial facilities. The true incidence of disease is
98 significantly under-estimated by national data: two studies conducted in central Cambodia
99 between 2006 and 2008 extrapolated expansion factors from single-province active surveillance
100 and described under-estimation of total dengue cases by national surveillance methods ranging
101 from 3.9- to 29.0-fold.^{13,14} With novel interventions and vaccines on the horizon, it is paramount
102 to improve estimates of dengue burden in countries such as Cambodia to better guide
103 containment strategies and vaccine rollout campaigns.

104
105 In this report we analyze nearly two decades of Cambodian national dengue surveillance data
106 from 2002 through 2020 and compare findings to those derived from a longitudinal pediatric
107 cohort study to describe recent trends in dengue case characteristics and incidence.

108 **Methods**

109 *National Surveillance for Dengue Cases*

110 The Cambodia National Dengue Control Program collects monthly data on hospitalized dengue
111 cases at public healthcare facilities. WHO clinical case definitions are applied to make a clinical
112 diagnosis of dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome
113 (DSS). Serologic confirmatory testing is performed in a minority of cases using the SD
114 BIOLINE Dengue Duo rapid test (Abbott®), depending on the patient's ability to afford the test
115 and the availability of test kits. In addition, the Virology Unit at Institut Pasteur du Cambodge
116 confirms dengue serotype using a specific RT-PCR in a subset of patient samples submitted by
117 sentinel sites.¹⁵ Sentinel surveillance was introduced in 5 provinces in 2001, with subsequent
118 expansion to 10 provinces in 2020 and 15 provinces in 2021. Patients are treated according to the
119 Cambodian National Guidelines for Clinical Management of Dengue 2018.¹⁶

120

121 *Census Data*

122 Census data was obtained from the 1998, 2008, and 2019 national Cambodian population census.
123 Population growth rate was computed using the exponential growth formula to extrapolate data
124 for inter-census years.¹⁷

125

126 *Pediatric Cohort Study*

127 A prospective longitudinal cohort study of 771 children aged two to nine years was conducted in
128 the province of Kampong Speu, Cambodia to investigate the relationship between dengue
129 infection and host immunological response to *Ae. aegypti* mosquito saliva (NCT03534245).¹⁸
130 Children were followed semi-annually from July 2018 through September 2021 with serial
131 serologic testing using dengue IgG ELISA (PanBio Dengue Indirect IgG, Abbott Laboratories)
132 and PRNT, as previously described.¹⁸ Children who developed symptoms consistent with acute
133 dengue were evaluated as unscheduled sick visits, during which rapid dengue testing (SD Bioline
134 DengueDuo NS1 Ag/immunoglobulin M [IgM]/IgG) was performed followed by confirmatory
135 dengue PCR. Clinically inapparent cases of dengue were identified, defined as children who had
136 negative dengue IgG ELISA at baseline and developed mono- or multitypic immunity (PRNT₅₀
137 >1:40) during the study period. There was moderate loss to follow-up from mid-2020 onwards as

138 a result of the global COVID-19 pandemic; due to paucity of data during this period, data was
139 censored at the 4th study visit in April 2020.

140

141 *Study Oversight and Ethics Statement*

142 National dengue surveillance data used in this study were de-identified and are publicly available
143 by request from the Cambodian Ministry of Health. Monthly dengue incidence is also accessible
144 via WHO weekly reports.¹⁹ The U.S. National Institutes of Health and the National Ethics
145 Committee on Human Research in Cambodia gave ethical approval for this work (pediatric
146 protocol NCT03534245).

147

148 *Statistical Analysis*

149 Crude dengue case data were collected from January 2002 to December 2020. Overall case and
150 age-specific incidence rates were calculated using population data derived from 1998, 2008, and
151 2019 census (as above). Age-adjusted incidence was calculated by multiplying age-specific
152 incidence and weighting of each age strata derived from 1998 census data.¹² Longitudinal trends
153 in dengue incidence, demographics, and case characteristics were explored using generalized
154 additive models fitted to annual case data, with a monthly smoothing term (Supplemental Text
155 S1). Two expansion factors were calculated by comparing dengue incidence in the pediatric
156 cohort to that reported via national surveillance. Expansion factor 1 (EF_1) represented under-
157 detection of clinically apparent dengue and was calculated by determining the average incidence
158 rate ratio of apparent dengue cases detected through active febrile surveillance in the pediatric
159 cohort (P_A) to that detected by national surveillance during July 2018-April 2020 for the same
160 age group (children aged 2-9 years) living in Kampong Speu (P_N). This was performed by fitting
161 a Poisson generalized linear model via quasilielihood to allow for variance inflation, adjusting
162 for month as a categorical variable. Expansion factor 2 (EF_2) represented under-detection of both
163 clinically apparent and inapparent dengue and was calculated by dividing the cumulative
164 incidence of apparent and inapparent dengue cases detected at semi-annual surveillance
165 timepoints in pediatric cohort (P_T) by semi-annual cumulative incidence of dengue cases in the
166 corresponding age group in Kampong Speu detected by national surveillance (P_{N6}). Statistical
167 analyses were performed in R (version 4.1.0).

168 **Results**

169 *Nationally Reported Dengue Incidence in Cambodia 2002-2020*

170 Cases of dengue across 25 Cambodian provinces were reported on a weekly basis and collated in
171 a central database. Over 19 years of national surveillance, a total of 353,270 cases were reported,
172 corresponding to an average age-adjusted incidence of 1.75 cases/ 1,000 persons/ year (Table 1).
173 Major epidemics occurred in 2007, 2012, and 2019 (Figure 1A). The 2019 epidemic was the
174 largest since national surveillance was implemented in 1980, with an annual total of 68,597 cases
175 (age-adjusted incidence 6.27 cases/ 1,000 persons/ year), a 3.91-fold increase from the average
176 across prior years and a 1.64-fold increase from the average in other epidemic years (2007,
177 2012). Annual peaks in dengue cases occurred in June through August, coinciding with the
178 country's annual wet season and periods of heavy rainfall (Figure 1B).²⁰ Siem Reap and Phnom
179 Penh provinces reported the highest case incidence (average 3.00 and 2.03 cases/ 1,000 persons/
180 year, respectively) (Supplementary Figure 1). Generalized additive models were fitted to dengue
181 cases from 2002 to 2020 and demonstrated a significant increase in both crude case numbers
182 (slope = 0.042, SE = 0.00031, $p < 0.001$) and age-adjusted incidence (slope = 0.0058, SE =
183 0.0021, $p = 0.006$), representing a 2.1-fold increase in both metrics over the 19-year period
184 (Figure 2 and Supplementary Table 1).

185

186 *Changes in Dengue Case Characteristics Over Time*

187 Dengue cases were evenly distributed by gender (51% male, 49% female), and mean age of
188 infected individuals across the entire period was 7.7 years (SD 5.8). In a generalized additive
189 model, predicted mean age of infected individuals increased significantly from 5.8 years (SE 0.3)
190 in 2002 to 9.1 years (SE 0.4) in 2020 (slope = 0.18, SE = 0.0088, $p < 0.001$; Figure 3A and
191 Supplementary Table 1). The trend of increasing age with time was sustained within different
192 case phenotypes (dengue fever: slope = 0.17, SE = 0.011, $p < 0.001$; dengue hemorrhagic fever:
193 slope = 0.20, SE = 0.0095, $p < 0.001$; dengue shock syndrome: slope = 0.13, SE = 0.012, p
194 < 0.001 ; Supplementary Figure 3). DF represented the majority (51%) of overall cases across the
195 entire study period, with DHF and DSS representing 45% and 4%, respectively. Average annual
196 case fatality rate was 0.57% (SD 0.48). Generalized additive models demonstrated decreasing
197 proportions of severe dengue among overall cases (DHF: 47.8% in 2002 to 42.6% in 2020, slope
198 = -0.012, SE = 0.00062, $p < 0.001$; DSS: 6.7% in 2002 to 2.3% in 2020, slope = -0.061, SE =

199 0.0016, $p < 0.001$), and decreasing case fatality rates (1.77% in 2002 to 0.10% in 2020, slope = -
200 0.16, SE = 0.0050, $p < 0.001$) from 2002 to 2020 (Figure 3B-D and Supplementary Table 1).
201 Dengue serotype-specific RT-PCR was performed on a monthly basis in a subset of cases from
202 sentinel sites. Across all years, DENV-2 was the most prevalent serotype (37.1%) followed by
203 DENV-1 (32.2%), DENV-3 (22.6%), and DENV-4 (8.1%). There was significant yearly
204 variation: the 2007 major epidemic was predominantly driven by DENV-3, while subsequent
205 years saw alternating DENV-1 and DENV-2 predominance including the 2012 epidemic driven
206 by DENV-1 and the 2019 epidemic driven by a mix of DENV-1 and DENV-2 (Supplementary
207 Figure 3).

208

209 *Comparisons of Data from National Surveillance Data and a Longitudinal Cohort Study*

210 In July 2018, 771 children aged 2 to 9 years living in the province of Kampong Speu were
211 enrolled in a community-based pediatric cohort study.¹⁸ Between July 2018-April 2020, a total of
212 51 clinically apparent, laboratory-confirmed dengue cases were identified (average monthly
213 incidence (P_A) of 3.0 per 1,000 persons (range: 0-22.0)) (Table 2). During the same period,
214 national surveillance captured an average monthly incidence (P_N) of 0.6 per 1,000 persons
215 (range: 0.01-2.4) in the same age group and in the same province. The average case incidence
216 ratio of $P_A:P_N$ was calculated to give an expansion factor (EF_1) of 5.0 (95% CI 0.2-26.5). Among
217 597 children identified as immunologically naïve to dengue infection based on PRNT data at
218 baseline assessment, there were a total of 148 cases of clinically inapparent seroconversions
219 identified during July 2018-April 2020. The cumulative incidence of all dengue cases (P_T ;
220 including both clinically apparent and inapparent cases) in the cohort was calculated at each 6-
221 monthly study interval (average 6-monthly cumulative incidence 135.9 cases per 1,000 persons,
222 range: 44.7-239.4) and compared to the corresponding 6-monthly cumulative incidence of
223 apparent dengue cases detected by national surveillance (P_{N6} ; average 4.4 cases per 1,000
224 persons, range: 2.3-8.4); the ratio of $P_T:P_{N6}$ gave an expansion factor (EF_2) of 33.6 (range: 18.7-
225 53.7).

226

227 **Discussion**

228 Cambodia is in a dramatic state of change with accelerated rural-to-urban migration, climate
229 change, land-use transformation, infrastructure development, and demographic and socio-
230 economic shifts within its population. The dynamic milieu affects transmissibility of vector-
231 borne disease and poses challenges to accurate modeling of dengue burden in this hyper-endemic
232 country. Data from 19 years of national dengue surveillance in Cambodia show a greater than
233 two-fold increase in dengue from 2002-2020, and a shift in the bulk of disease burden to older
234 pediatric age groups. When compared with data from a local longitudinal pediatric cohort,
235 national surveillance appears to under-estimate incidence by 5.0-fold for clinically apparent
236 cases and 33.6-fold for both apparent and inapparent cases in Kampong Speu province.

237
238 Dengue is also increasing in other areas of Southeast Asia.^{2,21} Understanding the root causes of
239 disease expansion can be challenging in countries where national surveillance is passive and
240 inconsistent. While changes in surveillance practices could contribute to an apparent increase in
241 cases, our comparison of national data with local cohort surveillance in 2018-2020 demonstrated
242 comparable underreporting of dengue burden with that identified in previous work from earlier
243 years.^{13,14} If we assume that national dengue reporting systems in Cambodia have remained fixed
244 through time, possible explanations for the observed increase in dengue cases from 2002-2020
245 include: i) a steady increase in susceptible hosts, such as due to population growth (though we
246 note that because dengue incidence increased as well, changes in population size alone cannot
247 explain the observed rise), and ii) an increase in transmission intensity, such as due to increasing
248 population density, a growing vector pool, altered vector/ host behavior leading to heightened
249 exposure, or evolving viral pathogenicity.²² Most likely, there are multifold contributors, and a
250 multifaceted approach is needed to reduce transmission intensity.

251
252 We noted a concurrent increase in mean age of dengue infection in Cambodia between 2002 and
253 2020, predominantly driven by an increase in age-specific incidence in the 10-14 year age group.
254 This effect may be underestimated due to poor clinical recognition of dengue cases in non-
255 pediatric populations in Cambodia.²³ The shift of dengue to older populations has been described
256 in other SEA countries and attributed to demographic transitions resulting from
257 industrialization.^{9,24,25} However, changes in the age distribution of the overall population alone

258 are unlikely to account for this shift, as even within age strata we noted different behavior of age-
259 specific incidence with time: for example, incidence was stagnant or decreasing for ages <10
260 years but increasing for ages 10-14 years. More likely, socioeconomic development leading to
261 altered human behavior and vector habitats may have moved the host:vector interface away from
262 the home and into public spaces such as schools and workplaces. Dengue has been classically
263 described as a disease of the young, but recent trends may indicate the need for a paradigm shift.
264 Recognizing the changing demographic of dengue, it is critical that interventions such as
265 vaccination be planned using accurate age-specific data to identify appropriate target
266 populations.

267
268 Disease under-detection is a problem in most dengue-endemic countries and various modeling
269 methods have been proposed to address the issue.^{6,7,26} Two previous studies aimed to measure
270 the degree of under-estimation of clinically apparent dengue in Kampong Cham province,
271 Cambodia, between 2006 and 2008. They found 9.1-fold¹³ and 3.9 to 29.0-fold (variation by
272 year)¹⁴ more symptomatic dengue cases detected with active surveillance of pediatric cohorts
273 compared to national data, respectively. Neither study examined inapparent infection. Here, we
274 applied data from a pediatric cohort in Kampong Speu province and found a 5.0-fold higher rate
275 of clinically apparent dengue in cohort versus national data between 2018 and 2020. Varying
276 rates of dengue and quality of healthcare infrastructure among provinces and over time are
277 among multiple factors affecting surveillance fidelity – this is reflected by the wide variation of
278 expansion factors reported here and elsewhere.⁶ An additional finding from our cohort was the
279 high incidence of clinically inapparent dengue, accounting for an additional 6-fold
280 underestimation of total case numbers. Ultimately, accurate capture of both clinically apparent
281 and inapparent dengue is needed, for instance, to identify areas with high transmission that could
282 benefit from vector control or populations with monotypic immunity for vaccination. Febrile and
283 serologic surveillance should occur in tandem to inform public health interventions.²⁶

284
285 Dengue control is a global health priority.¹ Fortunately, despite increasing dengue incidence in
286 Cambodia over the past two decades, the proportion of severe manifestations of dengue and case
287 fatality rates have declined. This is likely due to socioeconomic progress leading to improving
288 overall population health (increased access to care, fewer co-morbidities). Additionally, the

289 National Dengue Control Program has focused on intensive education and in-service campaigns
290 for nurses and doctors over the last few years,²⁷ and has urged treatment of dengue patients
291 within the decentralized national health system instead of at unregulated private practices.¹⁶
292 These improvements may have enabled earlier recognition and appropriate management of cases,
293 and are overall an encouraging sign that public health efforts in Cambodia are producing positive
294 results.

295
296 This study has several limitations. Effects of climate, migration, changing surveillance practices,
297 advances in clinical knowledge, improvements in health infrastructure, and periodic boosting of
298 public and provider awareness could not be accounted for given inconsistent collection of these
299 data over the 19-year period. The last comprehensive assessment of dengue epidemiology in
300 Cambodia included an evaluation of vector control, but this analysis could not be repeated due to
301 limited updated data.¹²

302

303 **Conclusion**

304 The incidence of dengue in Cambodia has increased significantly over the past two decades and
305 disease burden is shifting to older pediatric populations. True burden continues to be under-
306 estimated, although there have been notable successes of national programs reflected by a
307 reduction in cases of severe dengue and case fatality rates. Future interventions such as vaccine
308 campaigns or vector control will need to account for under-estimation and shifting demographics
309 to target susceptible populations at the appropriate scale.

310

311 **Acknowledgements**

312 The authors would like to acknowledge the staff at the National Dengue Control Program and the
313 National Center of Parasitology, Entomology, and Malaria Control in Cambodia for their
314 contributions to dengue surveillance, control, and reporting.

315

316 **Funding Statement**

317 This study was funded in part by the Intramural Research Program of the National Institute of
318 Allergy and Infectious Diseases at the National Institutes of Health (U.S.A.), and by the Merck
319 Investigator Studies Program (Award #60826).

320

321 **Data Availability Statement**

322 All data produced in the present study are available upon reasonable request to the authors.

323 References

- 324 1. World Health Organization. Dengue and severe dengue. World Health Organization,
325 Geneva, 2021. Accessed August 31, 2021. [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue)
326 [sheets/detail/dengue-and-severe-dengue](https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue)
- 327 2. Simmons CP, Farrar JJ, Nguyen van VC, Wills B. Dengue. *N Engl J Med*.
328 2012;366(15):1423-1432. doi:10.1056/NEJMra1110265
- 329 3. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine
330 Safety and Efficacy. *New England Journal of Medicine*. 2018;379(4):327-340.
331 doi:10.1056/NEJMoa1800820
- 332 4. Biswal S, Borja-Tabora C, Martinez Vargas L, et al. Efficacy of a tetravalent dengue
333 vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3
334 trial. *Lancet*. 2020;395(10234):1423-1433. doi:10.1016/S0140-6736(20)30414-1
- 335 5. Kallas EG, Precioso AR, Palacios R, et al. Safety and immunogenicity of the tetravalent,
336 live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind,
337 randomised placebo-controlled phase 2 trial. *Lancet Infect Dis*. 2020;20(7):839-850.
338 doi:10.1016/S1473-3099(20)30023-2
- 339 6. Undurraga EA, Halasa YA, Shepard DS. Use of expansion factors to estimate the burden of
340 dengue in Southeast Asia: a systematic analysis. *PLoS Negl Trop Dis*. 2013;7(2):e2056.
341 doi:10.1371/journal.pntd.0002056
- 342 7. Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis
343 from the Global Burden of Disease Study 2013. *Lancet Infect Dis*. 2016;16(6):712-723.
344 doi:10.1016/S1473-3099(16)00026-8
- 345 8. Grange L, Simon-Lorriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological
346 Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus
347 Infections. *Front Immunol*. 2014;5:280. doi:10.3389/fimmu.2014.00280
- 348 9. Katzelnick LC, Ben-Shachar R, Mercado JC, et al. Dynamics and determinants of the force
349 of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. *Proc Natl Acad Sci*
350 *U S A*. 2018;115(42):10762-10767. doi:10.1073/pnas.1809253115
- 351 10. Lopez AL, Adams C, Ylade M, et al. Determining dengue virus serostatus by indirect IgG
352 ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a
353 prospective population-based study. *Lancet Glob Health*. 2021;9(1):e44-e51.
354 doi:10.1016/S2214-109X(20)30392-2
- 355 11. Reiner RC, Stoddard ST, Forshey BM, et al. Time-varying, serotype-specific force of
356 infection of dengue virus. *Proc Natl Acad Sci U S A*. 2014;111(26):E2694-2702.
357 doi:10.1073/pnas.1314933111

- 358 12. Huy R, Buchy P, Conan A, et al. National dengue surveillance in Cambodia 1980–2008:
359 epidemiological and virological trends and the impact of vector control. *Bulletin of the*
360 *World Health Organization*. 2010;88(9):650. doi:10.2471/BLT.09.073908
- 361 13. Wichmann O, Yoon IK, Vong S, et al. Dengue in Thailand and Cambodia: An Assessment
362 of the Degree of Underrecognized Disease Burden Based on Reported Cases. *PLoS Negl*
363 *Trop Dis*. 2011;5(3):e996. doi:10.1371/journal.pntd.0000996
- 364 14. Vong S, Goyet S, Ly S, et al. Under-recognition and reporting of dengue in Cambodia: a
365 capture-recapture analysis of the National Dengue Surveillance System. *Epidemiol Infect*.
366 2012;140(3):491-499. doi:10.1017/S0950268811001191
- 367 15. Ou TP, Yun C, Auerswald H, et al. Improved detection of dengue and Zika viruses using
368 multiplex RT-qPCR assays. *Journal of Virological Methods*. 2020;282:113862.
369 doi:10.1016/j.jviromet.2020.113862
- 370 16. Cambodian Ministry of Health. National Guideline for Clinical Management of Dengue
371 (Version 3). Published online 2018. Accessed October 28, 2021.
372 [https://niph.org.kh/niph/uploads/library/pdf/GL055_National_guideline_for_CIM_Dengue.](https://niph.org.kh/niph/uploads/library/pdf/GL055_National_guideline_for_CIM_Dengue.pdf)
373 pdf
- 374 17. The World Bank. World Development Indicators. Accessed October 29, 2021.
375 <https://databank.worldbank.org/metadataglossary/2/series/SP.POP.GROW>
- 376 18. Manning JE, Chea S, Parker DM, et al. Development of inapparent dengue associated with
377 increased antibody levels to *Aedes aegypti* salivary proteins: a longitudinal dengue cohort
378 in Cambodia. *J Infect Dis*. Published online October 27, 2021;jiab541.
379 doi:10.1093/infdis/jiab541
- 380 19. World Health Organization Regional Office for the Western Pacific. Dengue Situation
381 Updates. Published online 2020. <http://iris.wpro.who.int/handle/10665.1/14461>
- 382 20. Cousien A, Ledien J, Souv K, et al. Predicting Dengue Outbreaks in Cambodia. *Emerg*
383 *Infect Dis*. 2019;25(12):2281-2283. doi:10.3201/eid2512.181193
- 384 21. Du M, Jing W, Liu M, Liu J. The Global Trends and Regional Differences in Incidence of
385 Dengue Infection from 1990 to 2019: An Analysis from the Global Burden of Disease
386 Study 2019. *Infect Dis Ther*. 2021;10(3):1625-1643. doi:10.1007/s40121-021-00470-2
- 387 22. Katzelnick LC, Coello Escoto A, Huang AT, et al. Antigenic evolution of dengue viruses
388 over 20 years. *Science*. 2021;374(6570):999-1004. doi:10.1126/science.abk0058
- 389 23. Bohl Jennifer A., Lay Sreyngim, Chea Sophana, et al. Discovering disease-causing
390 pathogens in resource-scarce Southeast Asia using a global metagenomic pathogen
391 monitoring system. *Proceedings of the National Academy of Sciences*.
392 2022;119(11):e2115285119. doi:10.1073/pnas.2115285119

- 393 24. Cummings DAT, Iamsirithaworn S, Lessler JT, et al. The Impact of the Demographic
394 Transition on Dengue in Thailand: Insights from a Statistical Analysis and Mathematical
395 Modeling. *PLoS Med.* 2009;6(9):e1000139. doi:10.1371/journal.pmed.1000139
- 396 25. Rodríguez-Barraquer I, Buathong R, Iamsirithaworn S, et al. Revisiting Rayong: Shifting
397 Seroprofiles of Dengue in Thailand and Their Implications for Transmission and Control.
398 *American Journal of Epidemiology.* 2014;179(3):353-360. doi:10.1093/aje/kwt256
- 399 26. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue.
400 *Nature.* 2013;496(7446):504-507. doi:10.1038/nature12060
- 401 27. Handel AS, Ayala EB, Borbor-Cordova MJ, et al. Knowledge, attitudes, and practices
402 regarding dengue infection among public sector healthcare providers in Machala, Ecuador.
403 *Trop Dis Travel Med Vaccines.* 2016;2:8. doi:10.1186/s40794-016-0024-y
- 404 28. Wood SN. MgcV: GAMs and generalized ridge regression for R. *R News.* 2001;1(2):20-25.
405

406 **Tables and Figure Legends**

Table 1: Demographic and Geographic Characteristics of Dengue Cases in Cambodia, 2002-2020

Characteristic	All Years (N=353,270)	2002-2007 (N=100,046)	2008-2013 (N=109,619)	2014-2020 (N=143,605)
Diagnosis, N (%)				
Dengue fever	180,914 (51)	50,334 (50)	50,719 (46)	79,861 (56)
Dengue hemorrhagic fever	158,536 (45)	44,278 (44)	54,437 (50)	59,821 (42)
Dengue shock syndrome	13,820 (4)	5,434 (5)	4,463 (4)	3,923 (3)
Case Fatality Rate, %	0.57	1.19	0.43	0.19
Gender, N (%)				
Male	178,996 (51)	49,119 (49)	54,849 (50)	75,028 (52)
Female	174,274 (49)	50,927 (51)	54,770 (50)	68,577 (48)
Age in Years, Mean (SD)	7.7 (5.8)	6.4 (3.9)	6.9 (4.5)	9.2 (7.4)
Age-Adjusted Incidence (per 1,000 persons per year)	1.75	1.57	1.76	1.90
Age-Specific Incidence (1,000 persons/ year)				
<1 year	3.95	3.48	4.25	4.10
1-4 years	3.65	4.19	3.97	2.91
5-9 years	5.06	4.73	5.44	5.01
10-14 years	2.96	2.08	2.53	4.07
15-19 years	0.37	0.12	0.22	0.71
20-24 years	0.10	0.01	0.03	0.23
25-39 years	0.05	0.00	0.02	0.11
>=40 years	0.02	0.00	0.01	0.06
Case Incidence by Province (1,000 persons/ year)				
Banteay Meanchey	1.91	1.75	2.30	1.72
Battambang	0.60	0.30	0.54	0.90
Kampong Cham*	1.10	1.49	1.20	0.68

Kampong Chhnang	1.14	0.90	1.12	1.36
Kampong Speu	1.19	1.37	1.31	0.93
Kampong Thom	1.85	1.56	1.74	2.19
Kampot	0.53	0.57	0.52	0.52
Kandal	1.88	2.11	1.89	1.69
Kep	0.80	0.72	0.45	1.15
Koh Kong	0.64	0.38	0.67	0.83
Kratie	0.43	0.46	0.32	0.50
Mondul Kiri	1.47	0.06	0.09	3.86
Otdar Meanchey	1.96	1.32	1.72	2.71
Pailin	1.41	0.21	1.02	2.77
Phnom Penh	2.03	1.87	1.55	2.57
Preah Sihanouk	1.11	0.57	0.65	1.96
Preah Vihear	1.49	0.35	1.34	2.61
Prey Veng	0.82	0.91	1.00	0.58
Pursat	0.26	0.19	0.30	0.30
Ratanak Kiri	0.64	0.26	0.25	1.29
Siem Reap	3.00	2.49	3.54	2.98
Stung Treng	0.47	0.56	0.18	0.63
Svay Rieng	0.49	0.68	0.38	0.41
Takeo	0.89	1.57	0.81	0.36

*Including Tboung Khmum province, which was created from Kampong Cham province in 2013 and began reporting surveillance data from 2016

407
 408 **Figure 1.** A) Annual dengue incidence in Cambodia, 2002-2020. Absolute dengue case numbers
 409 represented by blue bars on the left y-axis, case incidence (cases/ 1,000 persons) represented by
 410 the red line on the right y-axis. B) Monthly dengue case numbers in Cambodia, by year (2002-
 411 2020), with colors corresponding to specific epidemic years vs. non-epidemic years, as indicated
 412 by legend.
 413

414 **Figure 2.** Generalized additive models (GAM) fitted to A) crude dengue case numbers and B)
 415 age-adjusted dengue case incidence in Cambodia from 2002 and 2020. Black lines depict crude
 416 cases (A) and age-adjusted incidence (B), respectively, while red line gives GAM projections
 417 excluding the effect of month. Translucent red shading corresponds to 95% confidence intervals
 418 by standard error.



419
 420 **Figure 3.** Generalized additive models of A) mean age of infected individuals, B) proportion of
 421 dengue hemorrhagic fever, C) proportion of dengue shock syndrome, and D) case fatality rate for
 422 all dengue cases in Cambodia from 2002 to 2020. Black line depicts mean age of infected
 423 individuals by month (A). Red lines depict GAM projections excluding the effect of month.
 424 Translucent shading corresponding to 95% confidence intervals by standard error.



425
 426 **Table 2:** Comparison of dengue case incidence in Kampong Speu province from cohort and
 427 national data sets, July 2018-April 2020



Month	Monthly Incidence of Apparent Dengue Cases (Cases/ 1000 persons)		6-monthly Incidence of All Dengue Cases (Cases/ 1000 persons)	
	National Surveillance (P_N)	Cohort (P_A)	National Surveillance (P_{N6})	Cohort (P_T)
Jul 2018	0.48	1.30		
Aug 2018	0.32	0.00		
Sep 2018	0.39	2.59		
Oct 2018	0.44	1.30		
Nov 2018	0.30	0.00		
Dec 2018	0.30	0.00		
Jan 2019	0.15	0.00	2.39	44.71
Feb 2019	0.10	1.30		
Mar 2019	0.31	2.59		
Apr 2019	0.40	2.59		
May 2019	0.88	3.89		
Jun 2019	1.86	7.78		

Jul 2019	2.43	22.05		
Aug 2019	2.43	11.67	8.42	239.38
Sep 2019	0.95	5.19		
Oct 2019	0.60	1.30		
Nov 2019	0.31	1.30		
Dec 2019	0.17	0.00		
Jan 2020	0.11	0.00		
Feb 2020	0.08	1.30		
Mar 2020	0.01	0.00		
Apr 2020	0.06	0.00	2.31	123.66

428



A**B**

A**B****C****D**